FDA-Approved Treatments for BCG-Unresponsive NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec—highlighting how each is administered, and share their impressions of the safety and efficacy of these agents.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Now Viewing

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

Video content above is prompted by the following:

Three new treatments for patients who are unresponsive to BCG were FDA approved in the last 5 years. Briefly discuss each of the following approved therapies and how are they are administered.
Pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec
What are your impressions of the safety and efficacy of these agents?